Iacopo Olivotto

List of Publications by Citations

296 papers	15,234 citations	58 h-index	118 g-index
367 ext. papers	19,222 ext. citations	6.2 avg, IF	6.13 L-index

#	Paper	IF	Citations
296	Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. *New England Journal of Medicine*, **2003**, 348, 295-303	59.2	928
295	Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. *Circulation*, **2000**, 101, 2817-22	16.7	648
294	Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. *Circulation*, **2006**, 114, 2232-9	16.7	614
293	Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. *Circulation*, **2000**, 102, 858-64	16.7	596
292	Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. *Circulation*, **2001**, 104, 2517-24	16.7	571
291	Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. *Circulation*, **2014**, 130, 484-95	16.7	554
290	Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. *New England Journal of Medicine*, **2003**, 349, 1027-35	59.2	552
289	Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. *Journal of the American College of Cardiology*, **2005**, 46, 470-6	15.1	514
288	Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. *Journal of the American College of Cardiology*, **2014**, 64, 83-99	15.1	407
287	Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. *Journal of the American College of Cardiology*, **2009**, 54, 220-8	15.1	304
286	Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. *Journal of the American College of Cardiology*, **2005**, 46, 480-7	15.1	262
285	Myofilament Protein Gene Mutation Screening and Outcome of Patients With Hypertrophic Cardiomyopathy. *Mayo Clinic Proceedings*, **2008**, 83, 630-638	6.4	261
284	Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. *Journal of the American College of Cardiology*, **2002**, 39, 301-7	15.1	261
283	Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. *Circulation*, **2011**, 124, 40-7	16.7	251
282	Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. *Circulation*, **2013**, 127, 575-84	16.7	244
281	Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. *Journal of the American College of Cardiology*, **1995**, 26, 1529-36	15.1	218
280	Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). *Circulation*, **2018**, 138, 1387-1398	16.7	210

279	Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. *Journal of the American College of Cardiology*, **2010**, 55, 1444-53	15.1	207
278	Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. *Journal of the American College of Cardiology*, **2008**, 52, 559-66	15.1	205
277	Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. *Journal of Medical Genetics*, **2017**, 54, 288-296	5.8	193
276	The case for myocardial ischemia in hypertrophic cardiomyopathy. *Journal of the American College of Cardiology*, **2009**, 54, 866-75	15.1	188
275	Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. *Journal of the American College of Cardiology*, **1999**, 33, 2044-51	15.1	182
274	Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC). *European Heart Journal*, **2019**, 40, 19-33	9.5	174
273	Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy. *Journal of the American College of Cardiology*, **2006**, 47, 1043-8	15.1	169
272	Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging. *Circulation: Heart Failure*, **2012**, 5, 535-46	7.6	165
271	Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy). *American Journal of Cardiology*, **2006**, 98, 960-5	3	160
270	Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet, The*, **2020**, 396, 759-769	40	149
269	Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. *Mayo Clinic Proceedings*, **2008**, 83, 630-8	6.4	132
268	Mutation E169K in junctophilin-2 causes atrial fibrillation due to impaired RyR2 stabilization. *Journal of the American College of Cardiology*, **2013**, 62, 2010-9	15.1	120
267	The coronary circulation and blood flow in left ventricular hypertrophy. *Journal of Molecular and Cellular Cardiology*, **2012**, 52, 857-64	5.8	117
266	Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. *European Heart Journal*, **2012**, 33, 1724-33	9.5	115
265	Usefulness of bedside testing for brain natriuretic peptide to identify right ventricular dysfunction and outcome in normotensive patients with acute pulmonary embolism. *American Journal of Cardiology*, **2006**, 97, 1386-90	3	115
264	Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression. *Europace*, **2010**, 12, 347-55	3.9	111
263	Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. *American Journal of Cardiology* , **2010**, 106, 261-7	3	111
262	Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. *Journal of the American College of Cardiology*, **2003**, 41, 315-21	15.1	111

261	Contemporary Natural History and Management of Nonobstructive Hypertrophic Cardiomyopathy. *Journal of the American College of Cardiology*, **2016**, 67, 1399-1409	15.1	101
260	Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. *Journal of the American College of Cardiology*, **2011**, 58, 839-48	15.1	101
259	International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM). *Circulation*, **2018**, 137, 1015-1023	16.7	95
258	Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Will there ever be a randomized trial?. *Journal of the American College of Cardiology*, **2007**, 50, 831-4	15.1	87
257	Utility of an integrated clinical, echocardiographic, and venous ultrasonographic approach for triage of patients with suspected pulmonary embolism. *American Journal of Cardiology*, **1998**, 82, 1230-5	3	84
256	Left ventricular apical ballooning syndrome as a novel cause of acute mitral regurgitation. *Journal of the American College of Cardiology*, **2007**, 50, 647-9	15.1	84
255	The familial hypertrophic cardiomyopathy-associated myosin mutation R403Q accelerates tension generation and relaxation of human cardiac myofibrils. *Journal of Physiology*, **2008**, 586, 3639-44	3.9	81
254	Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy. *Journal of the American College of Cardiology*, **2013**, 62, 449-57	15.1	78
253	Left atrial remodeling in hypertrophic cardiomyopathy and susceptibility markers for atrial fibrillation identified by cardiovascular magnetic resonance. *American Journal of Cardiology*, **2014**, 113, 1394-400	3	74
252	Association of persistent right ventricular dysfunction at hospital discharge after acute pulmonary embolism with recurrent thromboembolic events. *Archives of Internal Medicine*, **2006**, 166, 2151-6		72
251	Reevaluating the Genetic Contribution of Monogenic Dilated Cardiomyopathy. *Circulation*, **2020**, 141, 387-398	16.7	71
250	Prevalence and clinical correlates of QT prolongation in patients with hypertrophic cardiomyopathy. *European Heart Journal*, **2011**, 32, 1114-20	9.5	70
249	Clinical phenotype and outcome of hypertrophic cardiomyopathy associated with thin-filament gene mutations. *Journal of the American College of Cardiology*, **2014**, 64, 2589-2600	15.1	69
248	Multidimensional structure-function relationships in human cardiac myosin from population-scale genetic variation. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 6701-6	11.5	68
247	Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids). *JAMA Cardiology*, **2019**, 4, 918-927	16.2	67
246	Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy. *Circulation*, **2020**, 141, 828-842	16.7	66
245	Usefulness and safety of transcatheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy. *American Journal of Cardiology*, **2007**, 99, 1575-81	3	66
244	Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. *European Journal of Heart Failure*, **2016**, 18, 1106-18	12.3	64

243	Histological and Histometric Characterization of Myocardial Fibrosis in End-Stage Hypertrophic Cardiomyopathy: A Clinical-Pathological Study of 30 Explanted Hearts. *Circulation: Heart Failure*, **2016**, 9,	7.6	60
242	Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry. *Journal of the American College of Cardiology*, **2019**, 74, 2333-2345	15.1	60
241	Stress echo 2020: the international stress echo study in ischemic and non-ischemic heart disease. *Cardiovascular Ultrasound*, **2017**, 15, 3	2.4	59
240	Spatial relationship between coronary microvascular dysfunction and delayed contrast enhancement in patients with hypertrophic cardiomyopathy. *Journal of Nuclear Medicine*, **2008**, 49, 1090-6	8.9	58
239	Coronary vasodilator reserve is impaired in patients with hypertrophic cardiomyopathy and left ventricular dysfunction. *American Heart Journal*, **1998**, 136, 972-81	4.9	58
238	Efficacy of Ranolazine in Patients With Symptomatic Hypertrophic Cardiomyopathy: The RESTYLE-HCM Randomized, Double-Blind, Placebo-Controlled Study. *Circulation: Heart Failure*, **2018**, 11, e004124	7.6	56
237	Significance of sarcomere gene mutations analysis in the end-stage phase of hypertrophic cardiomyopathy. *American Journal of Cardiology*, **2014**, 114, 769-76	3	56
236	Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy. *Circulation: Heart Failure*, **2017**, 10,	7.6	55
235	Developmental origins of hypertrophic cardiomyopathy phenotypes: a unifying hypothesis. *Nature Reviews Cardiology*, **2009**, 6, 317-21	14.8	55
234	Quantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases: the case of hypertrophic cardiomyopathy. *Genome Medicine*, **2019**, 11, 5	14.4	54
233	Novel □actinin 2 variant associated with familial hypertrophic cardiomyopathy and juvenile atrial arrhythmias: a massively parallel sequencing study. *Circulation: Cardiovascular Genetics*, **2014**, 7, 741-50		53
232	Long-term Outcomes of Pediatric-Onset Hypertrophic Cardiomyopathy and Age-Specific Risk Factors for Lethal Arrhythmic Events. *JAMA Cardiology*, **2018**, 3, 520-525	16.2	52
231	A molecular screening strategy based on beta-myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy. *Journal of Cardiovascular Medicine*, **2006**, 7, 601-7	1.9	52
230	Significance of Late Gadolinium Enhancement at Right Ventricular Attachment to Ventricular Septum in Patients With Hypertrophic Cardiomyopathy. *American Journal of Cardiology*, **2015**, 116, 436-41	3	51
229	A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy. *Circulation*, **2020**, 142, 217-229	16.7	51
228	MR Imaging in Hypertrophic Cardiomyopathy: From Magnet to Bedside. *Radiology*, **2014**, 273, 329-48	20.5	50
227	Metabolomic fingerprint of heart failure in humans: a nuclear magnetic resonance spectroscopy analysis. *International Journal of Cardiology*, **2013**, 168, e113-5	3.2	50
226	Determinants of echocardiographic left atrial volume: implications for normalcy. *European Journal of Echocardiography*, **2011**, 12, 826-33		49

225	The Italian Registry for hypertrophic cardiomyopathy: a nationwide survey. *American Heart Journal*, **2005**, 150, 947-54	4.9	47
224	Defining phenotypes and disease progression in sarcomeric cardiomyopathies: contemporary role of clinical investigations. *Cardiovascular Research*, **2015**, 105, 409-23	9.9	46
223	Blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. *American Journal of Cardiology*, **2012**, 110, 715-9	3	46
222	The many faces of hypertrophic cardiomyopathy: from developmental biology to clinical practice. *Journal of Cardiovascular Translational Research*, **2009**, 2, 349-67	3.3	46
221	Role of Genetic Testing in Inherited Cardiovascular Disease: A Review. *JAMA Cardiology*, **2017**, 2, 1153-1160	16.2	45
220	Clinical Spectrum, Therapeutic Options, and Outcome of Advanced Heart Failure in Hypertrophic Cardiomyopathy. *Circulation: Heart Failure*, **2015**, 8, 1014-21	7.6	44
219	Signal-averaged P-wave duration and risk of paroxysmal atrial fibrillation in hyperthyroidism. *American Journal of Cardiology*, **1996**, 77, 266-9	3	44
218	Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States. *American Journal of Cardiology*, **2016**, 117, 1651-1654	3	43
217	Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Insights From the SHaRe Registry. *Circulation*, **2020**, 141, 1371-1383	16.7	43
216	The spectrum of myocarditis: from pathology to the clinics. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2019**, 475, 279-301	5.1	42
215	Research priorities in sarcomeric cardiomyopathies. *Cardiovascular Research*, **2015**, 105, 449-56	9.9	41
214	Echocardiography in patients with hypertrophic cardiomyopathy: usefulness of old and new techniques in the diagnosis and pathophysiological assessment. *Cardiovascular Ultrasound*, **2010**, 8, 7	2.4	40
213	Determinants of treatment strategies and survival in acute myocardial infarction: a population-based study in the Florence district, Italy: results of the acute myocardial infarction Florence registry (AMI-Florence). *European Heart Journal*, **2003**, 24, 1195-203	9.5	40
212	Role of Exercise Testing in Hypertrophic Cardiomyopathy. *JACC: Cardiovascular Imaging*, **2017**, 10, 1374-1386	8.4	39
211	Microvascular dysfunction, myocardial ischemia, and progression to heart failure in patients with hypertrophic cardiomyopathy. *Journal of Cardiovascular Translational Research*, **2009**, 2, 452-61	3.3	39
210	Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Anderson-Fabry disease. *European Journal of Heart Failure*, **2013**, 15, 1363-73	12.3	37
209	Prevalence of subcutaneous implantable cardioverter-defibrillator candidacy based on template ECG screening in patients with hypertrophic cardiomyopathy. *Heart Rhythm*, **2016**, 13, 457-63	6.7	36
208	Hemodynamic progression and outcome of asymptomatic aortic stenosis in primary care. *American Journal of Cardiology*, **2012**, 109, 718-23	3	34

207	Prevalence and clinical profile of troponin T mutations among patients with hypertrophic cardiomyopathy in tuscany. *American Journal of Cardiology*, **2003**, 92, 1358-62	3	34
206	Pre-discharge B-type natriuretic peptide predicts early recurrence of decompensated heart failure in patients admitted to a general medical unit. *European Journal of Heart Failure*, **2005**, 7, 566-71	12.3	34
205	Comparison of long-term outcome in anthracycline-related versus idiopathic dilated cardiomyopathy: a single centre experience. *European Journal of Heart Failure*, **2018**, 20, 898-906	12.3	34
204	An expert consensus document on the management of cardiovascular manifestations of Fabry disease. *European Journal of Heart Failure*, **2020**, 22, 1076-1096	12.3	33
203	Contemporary genetic testing in inherited cardiac disease: tools, ethical issues, and clinical applications. *Journal of Cardiovascular Medicine*, **2018**, 19, 1-11	1.9	33
202	Defining the diagnostic effectiveness of genes for inclusion in panels: the experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center. *Genetics in Medicine*, **2019**, 21, 284-292	8.1	32
201	B-lines with Lung Ultrasound: The Optimal Scan Technique at Rest and During Stress. *Ultrasound in Medicine and Biology*, **2017**, 43, 2558-2566	3.5	32
200	Pathogenesis of Hypertrophic Cardiomyopathy is Mutation Rather Than Disease Specific: A Comparison of the Cardiac Troponin T E163R and R92Q Mouse Models. *Journal of the American Heart Association*, **2017**, 6,	6	32
199	Improving survival rates of patients with idiopathic dilated cardiomyopathy in Tuscany over 3 decades: impact of evidence-based management. *Circulation: Heart Failure*, **2013**, 6, 913-21	7.6	32
198	Late sodium current inhibitors to treat exercise-induced obstruction in hypertrophic cardiomyopathy: an in vitro study in human myocardium. *British Journal of Pharmacology*, **2018**, 175, 2635-2652	8.6	31
197	Timing and significance of exercise-induced left ventricular outflow tract pressure gradients in hypertrophic cardiomyopathy. *American Journal of Cardiology*, **2010**, 106, 1301-6	3	31
196	Novel Approach Targeting the Complex Pathophysiology of Hypertrophic Cardiomyopathy: The Impact of Late Sodium Current Inhibition on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy (LIBERTY-HCM) Trial. *Circulation: Heart Failure*, **2016**, 9, e002764	7.6	30
195	Dynamic assessment of 'valvular reserve capacity' in patients with rheumatic mitral stenosis. *European Heart Journal Cardiovascular Imaging*, **2012**, 13, 476-82	4.1	30
194	Association of Obesity With Adverse Long-term Outcomes in Hypertrophic Cardiomyopathy. *JAMA Cardiology*, **2020**, 5, 65-72	16.2	29
193	Care in Specialized Centers and Data Sharing Increase Agreement in Hypertrophic Cardiomyopathy Genetic Test Interpretation. *Circulation: Cardiovascular Genetics*, **2017**, 10,		27
192	'End-stage' hypertrophic cardiomyopathy: from mystery to model. *Nature Clinical Practice Cardiovascular Medicine*, **2007**, 4, 232-3		27
191	Usefulness of Electrocardiographic Patterns at Presentation to Predict Long-term Risk of Cardiac Death in Patients With Hypertrophic Cardiomyopathy. *American Journal of Cardiology*, **2016**, 118, 432-9	3	27
190	Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy. *International Journal of Cardiology*, **2020**, 300, 191-195	3.2	27

189	Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators. *Circulation: Arrhythmia and Electrophysiology*, **2018**, 11, e005820	6.4	26
188	Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week. *Journal of the American College of Cardiology*, **2021**, 77, 922-936	15.1	26
187	Clinical Course and Significance of Hypertrophic Cardiomyopathy Without Left Ventricular Hypertrophy. *Circulation*, **2019**, 139, 830-833	16.7	25
186	The Portuguese Registry of Hypertrophic Cardiomyopathy: Overall results. *Revista Portuguesa De Cardiologia*, **2018**, 37, 1-10	1	25
185	Relationship of ECG findings to phenotypic expression in patients with hypertrophic cardiomyopathy: a cardiac magnetic resonance study. *International Journal of Cardiology*, **2013**, 167, 1038-45	3.2	25
184	Prognostic value of N-terminal pro-brain natriuretic Peptide in outpatients with hypertrophic cardiomyopathy. *American Journal of Cardiology*, **2013**, 112, 1190-6	3	25
183	Cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy: the importance of clinical context. *European Heart Journal Cardiovascular Imaging*, **2018**, 19, 601-610	4.1	23
182	Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic Cardiomyopathy. *JAMA Cardiology*, **2020**, 5, 83-91	16.2	23
181	Prognostic role of stress echocardiography in hypertrophic cardiomyopathy: The International Stress Echo Registry. *International Journal of Cardiology*, **2016**, 219, 331-8	3.2	22
180	Early results of sarcomeric gene screening from the Egyptian National BA-HCM Program. *Journal of Cardiovascular Translational Research*, **2013**, 6, 65-80	3.3	22
179	Clinical significance of atrial fibrillation in hypertrophic cardiomyopathy. *Current Cardiology Reports*, **2001**, 3, 141-6	4.2	22
178	Effectiveness of subcutaneous implantable cardioverter-defibrillator testing in patients with hypertrophic cardiomyopathy. *International Journal of Cardiology*, **2017**, 231, 115-119	3.2	21
177	Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy. *Circulation: Heart Failure*, **2020**, 13, e006853	7.6	21
176	The electrocardiogram in the diagnosis and management of patients with hypertrophic cardiomyopathy. *Heart Rhythm*, **2020**, 17, 142-151	6.7	21
175	Incident Atrial Fibrillation Is Associated With MYH7 Sarcomeric Gene Variation in Hypertrophic Cardiomyopathy. *Circulation: Heart Failure*, **2018**, 11, e005191	7.6	21
174	Myocardial blood flow and left ventricular functional reserve in hypertrophic cardiomyopathy: a NH gated PET study. *European Journal of Nuclear Medicine and Molecular Imaging*, **2017**, 44, 866-875	8.8	20
173	Impact of Demographic Features, Lifestyle, and Comorbidities on the Clinical Expression of Hypertrophic Cardiomyopathy. *Journal of the American Heart Association*, **2017**, 6,	6	20
172	Relationship between atrial fibrillation and blunted hyperemic myocardial blood flow in patients with hypertrophic cardiomyopathy. *Journal of Nuclear Cardiology*, **2009**, 16, 92-6	2.1	20

171	Effect of comorbidity on coronary reperfusion strategy and long-term mortality after acute myocardial infarction. *American Heart Journal*, **2006**, 151, 1094-1100	4.9	20
170	Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy. *European Heart Journal*, **2021**, 42, 1988-1996	9.5	20
169	Lack of Phenotypic Differences by Cardiovascular Magnetic Resonance Imaging in MYH7 (Myosin Heavy Chain)- Versus MYBPC3 (Myosin-Binding Protein C)-Related Hypertrophic Cardiomyopathy. *Circulation: Cardiovascular Imaging*, **2017**, 10,	3.9	19
168	Effects of aging on neuroendocrine activation in subjects and patients in the presence and absence of heart failure with left ventricular systolic dysfunction. *American Journal of Cardiology*, **1996**, 77, 1197-201	3	19
167	Spatial and Functional Distribution of Pathogenic Variants and Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy. *Circulation Genomic and Precision Medicine*, **2020**, 13, 396-405	5.2	19
166	Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet, The*, **2021**, 397, 2467-2475	40	19
165	The electrocardiogram in the diagnosis and management of patients with dilated cardiomyopathy. *European Journal of Heart Failure*, **2020**, 22, 1097-1107	12.3	18
164	The dilemma of left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy: do patients with gradients really deserve prophylactic defibrillators?. *European Heart Journal*, **2006**, 27, 1895-7	9.5	18
163	Grey zones in cardiomyopathies: defining boundaries between genetic and iatrogenic disease. *Nature Reviews Cardiology*, **2017**, 14, 102-112	14.8	17
162	Abnormalities in sodium current and calcium homoeostasis as drivers of arrhythmogenesis in hypertrophic cardiomyopathy. *Cardiovascular Research*, **2020**, 116, 1585-1599	9.9	16
161	Clinical Features and Natural History of PRKAG2 Variant Cardiac Glycogenosis. *Journal of the American College of Cardiology*, **2020**, 76, 186-197	15.1	16
160	Impact of Genotype on the Occurrence of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. *American Journal of Cardiology*, **2016**, 117, 1151-9	3	16
159	Molecular modeling of disease causing mutations in domain C1 of cMyBP-C. *PLoS ONE*, **2013**, 8, e59206	3.7	16
158	Temporal Trend of Age at Diagnosis in Hypertrophic Cardiomyopathy: An Analysis of the International Sarcomeric Human Cardiomyopathy Registry. *Circulation: Heart Failure*, **2020**, 13, e007230	7.6	16
157	Contemporary Insights Into the Genetics of Hypertrophic Cardiomyopathy: Toward a New Era in Clinical Testing?. *Journal of the American Heart Association*, **2020**, 9, e015473	6	15
156	Cardiac Resynchronization Therapy for End-Stage Hypertrophic Cardiomyopathy: The Need for Disease-Specific Criteria. *Journal of the American College of Cardiology*, **2018**, 71, 464-466	15.1	15
155	Early discharge after acute myocardial infarction in the current clinical practice. Community data from the AMI-Florence Registry, Italy. *International Journal of Cardiology*, **2007**, 114, 57-63	3.2	15
154	An Investigation of the Molecular Mechanism of Double cMyBP-C Mutation in a Patient with End-Stage Hypertrophic Cardiomyopathy. *Journal of Cardiovascular Translational Research*, **2015**, 8, 232-43	3.3	14

153	Midventricular obstruction and clinical decision-making in obstructive hypertrophic cardiomyopathy. *Herz*, **2006**, 31, 871-6	2.6	14
152	Impact of disease-causing mutations on inter-domain interactions in cMyBP-C: a steered molecular dynamics study. *Journal of Biomolecular Structure and Dynamics*, **2017**, 35, 1916-1922	3.6	13
151	Advantages and Perils of Clinical Whole-Exome and Whole-Genome Sequencing in Cardiomyopathy. *Cardiovascular Drugs and Therapy*, **2020**, 34, 241-253	3.9	13
150	The Portuguese Registry of Hypertrophic Cardiomyopathy: Overall results. *Revista Portuguesa De Cardiologia (English Edition)*, **2018**, 37, 1-10	0	13
149	Electrophysiological and Contractile Effects of Disopyramide in Patients With Obstructive Hypertrophic Cardiomyopathy: A Translational Study. *JACC Basic To Translational Science*, **2019**, 4, 795-813	8.7	13
148	Regulation of intracellular Na(+) in health and disease: pathophysiological mechanisms and implications for treatment. *Global Cardiology Science & Practice*, **2013**, 2013, 222-42	0.7	13
147	Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study. *Molecular Genetics and Metabolism*, **2020**, 131, 219-228	3.7	13
146	Cardiovascular screening in low-income settings using a novel 4-lead smartphone-based electrocardiograph (D-Heart). *International Journal of Cardiology*, **2017**, 236, 249-252	3.2	12
145	Histopathological comparison of intramural coronary artery remodeling and myocardial fibrosis in obstructive versus end-stage hypertrophic cardiomyopathy. *International Journal of Cardiology*, **2019**, 291, 77-82	3.2	12
144	Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy: a 2016 reappraisal. *European Journal of Nuclear Medicine and Molecular Imaging*, **2016**, 43, 2413-2422	8.8	12
143	Clinical and molecular classification of cardiomyopathies. *Global Cardiology Science & Practice*, **2012**, 2012, 4	0.7	12
142	Effects of myocardial fibrosis assessed by MRI on dynamic left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy: a retrospective database analysis. *BMJ Open*, **2012**, 2,	3	12
141	Prevalence and clinical significance of acquired left coronary artery fistulas after surgical myectomy in patients with hypertrophic cardiomyopathy. *Journal of Thoracic and Cardiovascular Surgery*, **2010**, 140, 1046-52	1.5	12
140	Systematic large-scale assessment of the genetic architecture of left ventricular noncompaction reveals diverse etiologies. *Genetics in Medicine*, **2021**, 23, 856-864	8.1	12
139	Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study. *Heart Rhythm*, **2020**, 17, 1107-1114	6.7	11
138	Chagas disease as a cause of heart failure and ventricular arrhythmias in patients long removed from endemic areas: an emerging problem in Europe. *Journal of Cardiovascular Medicine*, **2015**, 16, 817-23	1.9	11
137	Minimally Invasive and Noninvasive Hemodynamic Monitoring of the Cardiovascular System: Available Options and Future Perspectives. *Current Cardiology Reviews*, **2006**, 2, 37-39	2.4	11
136	Hypertrophic cardiomyopathy in the community: why we should care. *Nature Clinical Practice Cardiovascular Medicine*, **2005**, 2, 324-5		11

135	Associations Between Female Sex, Sarcomere Variants, and Clinical Outcomes in Hypertrophic Cardiomyopathy. *Circulation Genomic and Precision Medicine*, **2021**, 14, e003062	5.2	10
134	Clinical Profile of Cardiac Involvement in Danon Disease: A Multicenter European Registry. *Circulation Genomic and Precision Medicine*, **2020**, 13, e003117	5.2	10
133	Intraoperative Diagnosis of Anderson-Fabry Disease in Patients With Obstructive Hypertrophic Cardiomyopathy Undergoing Surgical Myectomy. *JAMA Cardiology*, **2017**, 2, 1147-1151	16.2	10
132	Timing of invasive septal reduction therapies and outcome of patients with obstructive hypertrophic cardiomyopathy. *International Journal of Cardiology*, **2018**, 273, 155-161	3.2	10
131	Factors associated with persistence of symptoms 1 year after COVID-19: A longitudinal, prospective phone-based interview follow-up cohort study.. *European Journal of Internal Medicine*, **2021**,	3.9	10
130	Baseline ECG Features and Arrhythmic Profile in Transthyretin Versus Light Chain Cardiac Amyloidosis. *Circulation: Heart Failure*, **2020**, 13, e006619	7.6	9
129	Genetic profile of hypertrophic cardiomyopathy in Tunisia: Is it different?. *Global Cardiology Science & Practice*, **2015**, 2015, 16	0.7	9
128	Distal extremity pain as a presenting feature of Fabry's disease. *Arthritis Care and Research*, **2011**, 63, 390-5	4.7	9
127	Multidisciplinary evaluation and management of obstructive hypertrophic cardiomyopathy in 2020: Towards the HCM Heart Team. *International Journal of Cardiology*, **2020**, 304, 86-92	3.2	9
126	The role of the electrocardiographic phenotype in risk stratification for sudden cardiac death in childhood hypertrophic cardiomyopathy. *European Journal of Preventive Cardiology*, **2021**,	3.9	9
125	Performance of the CHADS-VASc score in predicting new onset atrial fibrillation during hospitalization for community-acquired pneumonia. *European Journal of Internal Medicine*, **2019**, 62, 24-28	3.9	8
124	Genetic determinants of clinical phenotype in hypertrophic cardiomyopathy. *BMC Cardiovascular Disorders*, **2020**, 20, 516	2.3	8
123	Pattern and degree of left ventricular remodeling following a tailored surgical approach for hypertrophic obstructive cardiomyopathy. *Global Cardiology Science & Practice*, **2012**, 2012, 9	0.7	8
122	Clinical profile and outcome of cardiac involvement in MELAS syndrome. *International Journal of Cardiology*, **2019**, 276, 14-19	3.2	8
121	Validation of pixel-wise parametric mapping of myocardial blood flow with □□NH□PET in patients with hypertrophic cardiomyopathy. *European Journal of Nuclear Medicine and Molecular Imaging*, **2015**, 42, 1581-8	8.8	7
120	Heritability in genetic heart disease: the role of genetic background. *Open Heart*, **2019**, 6, e000929	3	7
119	Response to letter regarding article, "Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy". *Circulation*, **2013**, 128, e157	16.7	7
118	Hypertrophic cardiomyopathy: The need for randomized trials. *Global Cardiology Science & Practice*, **2013**, 2013, 243-8	0.7	7

117	Myocardial bridging and sudden death in hypertrophic cardiomyopathy: Salome drops another veil. *European Heart Journal*, **2009**, 30, 1549-50	9.5	7
116	The left ventricular outflow in hypertrophic cardiomyopathy: from structure to function. *Journal of Cardiovascular Translational Research*, **2009**, 2, 510-7	3.3	7
115	Effectiveness of a multidisciplinary chest pain unit for the assessment of coronary syndromes and risk stratification in the Florence area. *American Heart Journal*, **2002**, 144, 630-5	4.9	7
114	Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). *European Respiratory Journal*, **2021**, 57,	13.6	7
113	Cardioprotective Strategy for Patients With Nonmetastatic Breast Cancer Who Are Receiving an Anthracycline-Based Chemotherapy: A Randomized Clinical Trial. *JAMA Oncology*, **2021**, 7, 1544-1549	13.4	7
112	Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.. *Journal of the American College of Cardiology*, **2021**, 78, 2518-2532	15.1	7
111	INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy-a Randomised Intervention Trial with losartan). *Global Cardiology Science & Practice*, **2015**, 2015, 7	0.7	6
110	Targeted Medical Therapies for Hypertrophic Cardiomyopathy. *Current Cardiology Reports*, **2020**, 22, 10	4.2	6
109	Predicting Mortality Risk in Older Hospitalized Persons With COVID-19: A Comparison of the COVID-19 Mortality Risk Score with Frailty and Disability. *Journal of the American Medical Directors Association*, **2021**, 22, 1588-1592.e1	5.9	6
108	A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization-the first insight from the AC-TIVE Study. *European Journal of Preventive Cardiology*, **2021**,	3.9	6
107	Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy. *European Heart Journal*, **2021**, 42, 3932-3944	9.5	6
106	Coronary microvascular dysfunction and ischemia in hypertrophic cardiomyopathy. Mechanisms and clinical consequences. *Italian Heart Journal: Official Journal of the Italian Federation of Cardiology*, **2004**, 5, 572-80		6
105	Atrial Dysfunction Assessed by Cardiac Magnetic Resonance as an Early Marker of Fabry Cardiomyopathy. *JACC: Cardiovascular Imaging*, **2020**, 13, 2262-2264	8.4	5
104	Prescribing, dosing and titrating exercise in patients with hypertrophic cardiomyopathy for prevention of comorbidities: Ready for prime time. *European Journal of Preventive Cardiology*, **2020**, 2047487320928654	3.9	5
103	Dissecting functional impairment in hypertrophic cardiomyopathy by dynamic assessment of diastolic reserve and outflow obstruction: A combined cardiopulmonary-echocardiographic study. *International Journal of Cardiology*, **2017**, 227, 743-750	3.2	5
102	Tunneled left anterior descending artery in a child with hypertrophic cardiomyopathy. *Nature Clinical Practice Cardiovascular Medicine*, **2009**, 6, 134-9		5
101	Acceptability, Feasibility and Preliminary Evaluation of a Novel, Personalised, Home-Based Physical Activity Intervention for Chronic Heart Failure (Active-at-Home-HF): a Pilot Study. *Sports Medicine - Open*, **2019**, 5, 45	6.1	5
100	External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy. *European Journal of Preventive Cardiology*, **2021**,	3.9	5

99	Sex-related differences in exercise performance and outcome of patients with hypertrophic cardiomyopathy. *European Journal of Preventive Cardiology*, **2020**, 27, 1821-1831	3.9	5
98	Impact of cardiovascular involvement on the clinical course of paediatric mitochondrial disorders. *Orphanet Journal of Rare Diseases*, **2020**, 15, 196	4.2	5
97	Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy. *Current Cardiology Reports*, **2021**, 23, 79	4.2	5
96	Predictors of mortality and adverse events in patients with infective endocarditis: a retrospective real world study in a surgical centre. *BMC Cardiovascular Disorders*, **2021**, 21, 28	2.3	5
95	Cardiac involvement in eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome): Prospective evaluation at a tertiary referral centre. *European Journal of Internal Medicine*, **2021**, 85, 68-79	3.9	5
94	A machine learning-based risk stratification model for ventricular tachycardia and heart failure in hypertrophic cardiomyopathy. *Computers in Biology and Medicine*, **2021**, 135, 104648	7	5
93	Determinants of discrepancies between two-dimensional echocardiographic methods for assessment of maximal left atrial volume. *European Heart Journal Cardiovascular Imaging*, **2017**, 18, 584-602	4.1	4
92	Advances in Stem Cell Modeling of Dystrophin-Associated Disease: Implications for the Wider World of Dilated Cardiomyopathy. *Frontiers in Physiology*, **2020**, 11, 368	4.6	4
91	Design of the SILICOFCM study: Effect of sacubitril/valsartan vs lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy. *Clinical Cardiology*, **2020**, 43, 430-440	3.3	4
90	Channelopathies, cardiac hypertrophy, and the theory of light. *European Heart Journal*, **2018**, 39, 2908-2910	9.5	4
89	Looking for hypertrophic cardiomyopathy in the community: why is it important?. *Journal of Cardiovascular Translational Research*, **2009**, 2, 392-7	3.3	4
88	Syncope and ventricular arrhythmias in hypertrophic cardiomyopathy are not related to the derangement of coronary microvascular function. *European Heart Journal*, **1997**, 18, 1946-50	9.5	4
87	Emerging Medical Treatment for Hypertrophic Cardiomyopathy. *Journal of Clinical Medicine*, **2021**, 10,	5.1	4
86	Combined Effect of Mediterranean Diet and Aerobic Exercise on Weight Loss and Clinical Status in Obese Symptomatic Patients with Hypertrophic Cardiomyopathy. *Heart Failure Clinics*, **2021**, 17, 303-313	3.3	4
85	Disease-specific variant pathogenicity prediction significantly improves variant interpretation in inherited cardiac conditions. *Genetics in Medicine*, **2021**, 23, 69-79	8.1	4
84	Differences between familial and sporadic dilated cardiomyopathy: ESC EORP Cardiomyopathy & Myocarditis registry. *ESC Heart Failure*, **2021**, 8, 95-105	3.7	4
83	Clinical and Laboratory Follow-up After Hospitalization for COVID-19 at an Italian Tertiary Care Center. *Open Forum Infectious Diseases*, **2021**, 8, ofab049	1	4
82	Changes in the perceived epidemiology of amyloidosis: 20 year-experience from a Tertiary Referral Centre in Tuscany. *International Journal of Cardiology*, **2021**, 335, 123-127	3.2	4

81	Clinical presentation and long-term outcomes of infantile hypertrophic cardiomyopathy: a European multicentre study. *ESC Heart Failure*, **2021**,	3.7	4
80	Antiarrhythmic efficacy of anakinra in a young patient with autoimmune lymphocytic myocarditis. *Rheumatology*, **2020**, 59, e88-e90	3.9	3
79	Clinical and Molecular Aspects of Cardiomyopathies: Emerging Therapies and Clinical Trials. *Heart Failure Clinics*, **2018**, 14, 161-178	3.3	3
78	Left Ventricular Apex Involvement in Hypertrophic Cardiomyopathy. *Echocardiography*, **2015**, 32, 1575-80	1.5	3
77	On the Cardiac Loop and Its Failing: Left Ventricular Outflow Tract Obstruction. *Journal of the American Heart Association*, **2020**, 9, e014857	6	3
76	IN VIVO OBSERVATION OF RETINAL VASCULAR DEPOSITS USING ADAPTIVE OPTICS IMAGING IN FABRY DISEASE. *Retina*, **2020**, 40, 1623-1629	3.6	3
75	Computational prediction of protein subdomain stability in MYBPC3 enables clinical risk stratification in hypertrophic cardiomyopathy and enhances variant interpretation. *Genetics in Medicine*, **2021**, 23, 1281-1287	8.1	3
74	A computational pipeline for data augmentation towards the improvement of disease classification and risk stratification models: A case study in two clinical domains. *Computers in Biology and Medicine*, **2021**, 134, 104520	7	3
73	Letter regarding the article 'Heart failure with preserved ejection fraction: from mechanisms to therapies' by Lam and colleagues. *European Heart Journal*, **2019**, 40, 703-704	9.5	3
72	Transcatheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy: Long-term results and clinical outcomes. *Journal of Cardiovascular Electrophysiology*, **2021**, 32, 657-666	2.7	3
71	Stress Echo 2030: The Novel ABCDE-(FGLPR) Protocol to Define the Future of Imaging. *Journal of Clinical Medicine*, **2021**, 10,	5.1	3
70	Pathophysiology and Clinical Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy105-120		3
69	Response by Ho et al to Letter Regarding Article, "Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)". *Circulation*, **2019**, 139, 1559-1560	16.7	2
68	Coronary microvascular function is impaired in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. *European Journal of Neurology*, **2021**, 28, 3809-3813	6	2
67	Embolic risk stratification and prognostic impact of early surgery in left-sided infective endocarditis. *European Journal of Internal Medicine*, **2020**, 78, 82-87	3.9	2
66	Abrupt Onset of Refractory Heart Failure Associated With Light-Chain Amyloidosis in Hypertrophic Cardiomyopathy. *JAMA Cardiology*, **2017**, 2, 94-97	16.2	2
65	ECG-based screening: not only for athletes. *European Heart Journal*, **2007**, 28, 1170	9.5	2
64	Disease Progression of Hypertrophic Cardiomyopathy: Modeling Using Machine Learning.. *JMIR Medical Informatics*, **2022**, 10, e30483	3.6	2

63	Electromechanical dissociation of left atrium in patients with Cardiac Amyloidosis by Magnetic Resonance: Prognostic and clinical correlates. *IJC Heart and Vasculature*, **2020**, 31, 100633	2.4	2
62	Prevalence, causes and predictors of cardiovascular hospitalization in patients with hypertrophic cardiomyopathy. *International Journal of Cardiology*, **2020**, 318, 94-100	3.2	2
61	Prognostic Value of Reduced Heart Rate Reserve during Exercise in Hypertrophic Cardiomyopathy. *Journal of Clinical Medicine*, **2021**, 10,	5.1	2
60	Pathophysiology and Treatment of Hypertrophic Cardiomyopathy: New Perspectives. *Current Heart Failure Reports*, **2021**, 18, 169-179	2.8	2
59	Maximal Wall Thickness Measurement in Hypertrophic Cardiomyopathy: Biomarker Variability and its Impact on Clinical Care. *JACC: Cardiovascular Imaging*, **2021**, 14, 2123-2134	8.4	2
58	Arrhythmogenic potential of myocardial disarray in hypertrophic cardiomyopathy: genetic basis, functional consequences and relation to sudden cardiac death. *Europace*, **2021**, 23, 985-995	3.9	2
57	Use of Smartphone-operated ECG for home ECG surveillance in COVID-19 patients. *European Heart Journal Digital Health*, **2021**, 2, 175-178	2.3	2
56	Incidence of light chain amyloidosis in Florence metropolitan area, Italy: a population-based study. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2021**, 28, 211-212	2.7	2
55	Early Diagnosis and Outcome in Patients With Wild-Type Transthyretin Cardiac Amyloidosis. *Mayo Clinic Proceedings*, **2021**, 96, 2185-2191	6.4	2
54	The epidemiologic evolution and present perception of hypertrophic cardiomyopathy. *Italian Heart Journal: Official Journal of the Italian Federation of Cardiology*, **2003**, 4, 596-601		2
53	Participation in thrill-seeking activities by patients with hypertrophic cardiomyopathy: Individual preferences, adverse events and physician attitude. *American Heart Journal*, **2019**, 214, 28-35	4.9	1
52	Mitochondrial Energetics and Ca2-Activated ATPase in Obstructive Hypertrophic Cardiomyopathy. *Journal of Clinical Medicine*, **2020**, 9,	5.1	1
51	The eighth alternative to evidence based medicine in the early era of the COVID-19 pandemic: Too much emergency and emotion, too little evidence. *European Journal of Internal Medicine*, **2020**, 77, 163-164	3.9	1
50	Common presentation of rare cardiac diseases: Arrhythmias. *International Journal of Cardiology*, **2018**, 257, 351-357	3.2	1
49	Electrophysiological correlates of word recognition memory process in patients with ischemic left ventricular dysfunction. *Clinical Neurophysiology*, **2016**, 127, 3007-3013	4.3	1
48	Incremental prognostic value of multiparametric echocardiographic assessment for severe aortic stenosis. *International Journal of Cardiology*, **2014**, 172, e356-8	3.2	1
47	Reply: Obstructive sleep apnea and hypertrophic cardiomyopathy: obiter dictum or more?. *Journal of the American College of Cardiology*, **2014**, 64, 2562	15.1	1
46	Response to Letter Regarding Article, Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction *Circulation*, **2007**, 115,	16.7	1

45	Hypertrophic Cardiomyopathy in Anderson-Fabry Disease. *Clinical Therapeutics*, **2007**, 29, S93-S94	3.5	1
44	New concepts in hypertrophic cardiomyopathies. *Circulation*, **2002**, 105, e188; author reply e188	16.7	1
43	Sex-related differences in clinical presentation and all-cause mortality in patients with cardiac transthyretin amyloidosis and light chain amyloidosis.. *International Journal of Cardiology*, **2022**,	3.2	1
42	Myocardial blood flow in patients with hypertrophic cardiomyopathy receiving perindopril (CARAPaCE): a pilot study. *Journal of Cardiovascular Medicine*, **2021**, 22, 511-513	1.9	1
41	Epidemiology of cardiomyopathies: essential context knowledge for a tailored clinical work-up. *European Journal of Preventive Cardiology*, **2020**,	3.9	1
40	Mavacamten - a new disease-specific option for pharmacological treatment of symptomatic patients with hypertrophic cardiomyopathy. *Kardiologia Polska*, **2021**, 79, 949-954	0.9	1
39	Creatine deficiency and heart failure. *Heart Failure Reviews*, **2021**, 1	5	1
38	Syndrome of Reversible Cardiogenic Shock and Left Ventricular Ballooning in Obstructive Hypertrophic Cardiomyopathy. *Journal of the American Heart Association*, **2021**, 10, e021141	6	1
37	Sport practice in hypertrophic cardiomyopathy: running to stand still?. *International Journal of Cardiology*, **2021**, 345, 77-82	3.2	1
36	Quantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases: The case of hypertrophic cardiomyopathy		1
35	The genetic architecture of left ventricular non-compaction reveals both substantial overlap with other cardiomyopathies and a distinct aetiology in a subset of cases		1
34	Doctor-patient care relationship in genetic cardiomyopathies: An exploratory study on clinical consultations. *PLoS ONE*, **2020**, 15, e0236814	3.7	1
33	Is heart failure with preserved ejection fraction a 'dementia' of the heart?. *Heart Failure Reviews*, **2021**, 1	5	1
32	Endocarditis with spondylodiscitis: clinical characteristics and prognosis. *BMC Cardiovascular Disorders*, **2021**, 21, 186	2.3	1
31	Potential resistance to SARS-CoV-2 infection in lysosomal storage disorders. *CKJ: Clinical Kidney Journal*, **2021**, 14, 1488-1490	4.5	1
30	Standard ECG for differential diagnosis between Anderson-Fabry disease and hypertrophic cardiomyopathy. *Heart*, **2022**, 108, 54-60	5.1	1
29	Cardiogenic Shock in Obstructive Hypertrophic Cardiomyopathy Plus Apical Ballooning: Management With VA-ECMO and Myectomy. *JACC: Case Reports*, **2021**, 3, 433-437	1.2	1
28	Genetic testing in pediatric cardiomyopathies: Implications for diagnosis and management. *Progress in Pediatric Cardiology*, **2018**, 51, 24-30	0.4	1

27	Cardiomyopathies in children Inherited heart muscle disease: Overview of hypertrophic, dilated, restrictive and non-compaction phenotypes. *Progress in Pediatric Cardiology*, **2018**, 51, 8-15	0.4	1
26	Sex-related differences in ventricular remodeling after myocardial infarction. *International Journal of Cardiology*, **2021**, 339, 62-69	3.2	1
25	Racial Differences in Val122Ile associated Transthyretin Cardiac Amyloidosis.. *Journal of Cardiac Failure*, **2021**,	3.3	1
24	Sex-Related Differences in Genetic Cardiomyopathies.. *Journal of the American Heart Association*, **2022**, e024947	6	1
23	Clinical Features and Natural History of Preadolescent Nonsyndromic Hypertrophic Cardiomyopathy.. *Journal of the American College of Cardiology*, **2022**, 79, 1986-1997	15.1	1
22	A rare case of pediatric cardiomyopathy: Alstrm syndrome identified by gene panel analysis. *Clinical Case Reports (discontinued)*, **2020**, 8, 3369-3373	0.7	0
21	Sudden cardiac death in cardiomyopathies: acting upon "acceptable" risk in the personalized medicine era.. *Heart Failure Reviews*, **2022**, 1	5	0
20	The Influence of Genotype on the Phenotype, Clinical Course, and Risk of Adverse Events in Children with Hypertrophic Cardiomyopathy. *Heart Failure Clinics*, **2022**, 18, 1-8	3.3	0
19	Prevalence of Inherited Cardiac Diseases Among Young Patients Requiring Permanent Pacing. *Circulation: Arrhythmia and Electrophysiology*, **2021**, CIRCEP121010562	6.4	0
18	Neither Athletic Training nor Detraining Affects LV Hypertrophy in Adult, Low-Risk Patients With HCM. *JACC: Cardiovascular Imaging*, **2021**, 15, 170-170	8.4	0
17	Generation of virtual patient data for in-silico cardiomyopathies drug development using tree ensembles: a comparative study. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference*, **2020**, 2020, 5343-5346	0.9	0
16	Ventricular tachyarrhythmias and sudden cardiac death in light-chain amyloidosis: a clash of cardio-toxicities?. *British Journal of Haematology*, **2021**, 193, e27-e31	4.5	0
15	Plasmatic and myocardial microRNA profiles in patients with Hypertrophic Cardiomyopathy. *Clinical and Translational Medicine*, **2021**, 11, e435	5.7	0
14	The labyrinth of nomenclature in Cardiology. Eternal dilemmas and new challenges on the horizon in the personalized medicine era. *European Journal of Heart Failure*, **2021**, 23, 1062-1067	12.3	0
13	Mavacamten for hypertrophic obstructive cardiomyopathy - Authors' reply. *Lancet, The*, **2021**, 397, 369-370	40	0
12	Recognition of pre-hypertrophic cardiac involvement in Fabry Disease based on automated electrocardiographic measures. *International Journal of Cardiology*, **2021**, 338, 121-126	3.2	0
11	Metabolomics Fingerprint Predicts Risk of Death in Dilated Cardiomyopathy and Heart Failure.. *Frontiers in Cardiovascular Medicine*, **2022**, 9, 851905	5.4	0
10	Variational Gaussian Mixture Models with robust Dirichlet concentration priors for virtual population generation in hypertrophic cardiomyopathy: a comparison study. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference*, **2021**, 2021, 1674-1677	0.9	0

9	Genotype-Driven Pathogenesis of Atrial Fibrillation in Hypertrophic Cardiomyopathy: The Case of Different Mutations.. *Frontiers in Physiology*, **2022**, 13, 864547	4.6	0
8	Relationship Between Maximal Left Ventricular Wall Thickness and Sudden Cardiac Death in Childhood Onset Hypertrophic Cardiomyopathy.. *Circulation: Arrhythmia and Electrophysiology*, **2022**, CIRCEP121010075	6.4	0
7	Reply to: Is subcutaneous implantable cardioverter-defibrillator testing effective and safe for patients with hypertrophic cardiomyopathy?. *International Journal of Cardiology*, **2017**, 246, 55	3.2	
6	Genetic testing for hypertrophic cardiomyopathy: ongoing voyage from exploration to clinical exploitation. *Neurology International*, **2011**, 1, 3	0	
5	Stress Echocardiography in Hypertrophic Cardiomyopathy **2015**, 551-568		
4	Microvascular ischaemia after cardiac arrest in a patient with hypertrophic cardiomyopathy. *Global Cardiology Science & Practice*, **2015**, 2015, 51	0.7	
3	Age-dependent diagnostic yield of echocardiography as a second-line diagnostic investigation in athletes with abnormalities at preparticipation screening. *Journal of Cardiovascular Medicine*, **2021**, 22, 759-766	1.9	
2	Can anthropology improve our care of inherited cardiac arrhythmias? A modest proposal. *Heart Rhythm*, **2016**, 13, 2395-2398	6.7	
1	Comment on: Assessment of cardiac disease in MELAS requires comprehensive, prospective work-up. *International Journal of Cardiology*, **2019**, 280, 162	3.2	